AT 101

Drug Profile

AT 101

Alternative Names: (-)-gossypol; AT-101; Bcl-2/xL inhibitor - 3SBio; R-(-)-gossypol acetic acid

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer 3SBio; Ascenta Therapeutics; Mayo Clinic; National Cancer Institute (USA)
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Multiple myeloma
  • Preclinical Leukaemia; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Glioblastoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 20 Oct 2016 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02697344)
  • 15 Mar 2016 Biomarkers information updated
  • 11 Mar 2016 Mayo Clinic plans a phase I/II trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (NCT02697344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top